Tablets tainted with N-nitrosodiethylamine, a suspected human carcinogen
FRIDAY, Sept. 14, 2018 (HealthDay News) — The U.S. Food and Drug Administration warns that it has found a second impurity in three lots of Torrent Pharmaceuticals’ valsartan drug products.
The FDA first recalled valsartan medicines back in July, after the Chinese company that makes the drugs, Zhejiang Huahai Pharmaceuticals, found a contaminant called N-nitrosodimethylamine (NDMA) in several batches of its active ingredient, valsartan API.
In a news release issued yesterday, the FDA said Torrent’s valsartan 160 mg (lot BV47D001) and 320 mg (lots BV48D001 and BV48D002) tablets are also tainted with N-nitrosodiethylamine (NDEA). NDEA is classified as a known animal and suspected human carcinogen by the U.S. Environmental Protection Agency.
Contamination by both NDMA and NDEA could result from a specific sequence of manufacturing steps and chemical reactions, the FDA explained. After NDMA was detected, the agency immediately began retesting all valsartan products, including the already recalled drugs and others sold in the United States, the agency explained. The FDA’s testing shows that not all products made using Zhejiang Huahai Pharmaceuticals’ valsartan API contain the potentially dangerous impurities.
Aircrew Face Higher Odds of Radiation-Related Cancer Deaths 
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors 
Couples" Coping Skills Help Reduce Depression in GI Cancer Survivors 
Genomic Newborn Screening Could ID Cancer Predisposition Syndrome 
Patient Education Increases Skin Cancer Screening in Stem Cell Transplant Survivors 
Real-World ARIA Incidence With Lecanemab Aligns With Clinical Trial Findings 
Subclinical Cardiac Dysfunction Linked to Neurodegeneration in APOE-ε4 Carriers 
Study IDs Gaps in Hereditary Breast Cancer Risk Assessment Before Gender-Affirming Mastectomy 
